The mechanism of action of α-phel in chronic pain was analyzed in vivo. Ethics Committee of UFPJ approved this project (protocol nº 305/17). Female Swiss mice (25-30g) underwent partial sciatic nerve ligation surgery to induce neuropathy. The neuropathic mice (N=8) were pre-treated with Naloxone (2mg/kg, i.p.) or Saline (10mL/kg, p.o.). After 20 minutes, they were treated with α-phel (6.25mg/kg, p.o.) or morphine (5mg/kg, i.p.) and evaluated by Von Frey test.

**Results:** The predicted pharmacokinetic parameters (Table 1) suggest good intestinal absorption and good permeability. Plasma protein binding is elevated, however, it is reversible and technological alternatives, such as carrier systems, can improve it. The α-phel does not inhibit CYP3A4, it indicates a minimal possibility of interactions with others drugs and adverse reactions.

**Table 1. Pharmacokinetic parameters of α-phel**

<table>
<thead>
<tr>
<th>ID</th>
<th>VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>BBB</td>
<td>7.17054</td>
</tr>
<tr>
<td>Buffer_solubility_mg_L</td>
<td>122708</td>
</tr>
<tr>
<td>Caco2</td>
<td>23.4164</td>
</tr>
<tr>
<td>CYPsubtype inhibition</td>
<td>Inhibitor</td>
</tr>
<tr>
<td>CYP_2C19 and 2C9 inhibition</td>
<td>Inhibitor</td>
</tr>
<tr>
<td>CYP_2D6_inhibition(substrate)</td>
<td>Non</td>
</tr>
<tr>
<td>CYP_3A4 inhibition</td>
<td>Non</td>
</tr>
<tr>
<td>CYP_3A4_strain</td>
<td>Weakly</td>
</tr>
<tr>
<td>HA</td>
<td>100.00000</td>
</tr>
<tr>
<td>MDCK</td>
<td>57.707</td>
</tr>
<tr>
<td>Pgp inhibition</td>
<td>Non</td>
</tr>
<tr>
<td>Plasma_Protein Binding</td>
<td>90.00000</td>
</tr>
<tr>
<td>Pure_waste_solvability</td>
<td>141.466</td>
</tr>
</tbody>
</table>

The structure of α-phel binding opioid receptors is shown in Figure 1. The lowest ligand-receptor binding energies were, respectively: -6.0 kcal/mol, -6.6 kcal/mol and -7.4 kcal/mol for the interaction of α-phel with Mu, Kappa and Delta receptors. It indicates that α-phel has high affinity for all three opioid receptors, binding in a strong and stable way.

The analgesic potential of the substance was tested in vivo as well. It was observed that Naloxone, an opioid antagonist, significantly reversed the effect of α-phel, indicating that it displays antinociceptive and antihyperalgesic activity through opioid system.

**Conclusion:** The monoterpene α-phel presents antinociceptive activity and reduces the sensitivity in chronic pain through the activation of opioid receptors.

Thus, in vivo and in silico results indicate that α-phel is an analgesic opioid agonist. This work may guide further preclinical studies, since α-phel may be an important strategy to treat chronic pain, with fewer side effects, dependence and tolerance than conventional drugs.

**References:**


**Disclosure of Interests:** None declared

**DOI:** 10.1136/annrheumdis-2020-eular.1166

---

**THU0452**

**ANTINOCICEPTIVE EFFECT OF A-PHELLANDRENE IN CHRONIC PAIN: IN SILICO PHARMACOKINETIC, MOLECULAR DOCKING AND IN VIVO EVALUATION**

Y. M. S. Pires1, M. C. Leal de Moura2, W. Amorim Dias3, V. D. Pimentel4.

1Federal University of Piaui, Teresina, Brazil; 2Federal University of Piaui, Teresina, Brazil; 3Federal University of Piaui, Teresina, Brazil; 4UNIFSA, Teresina, Brazil

**Background:** The pharmacological approaches of chronic pain are a challenge in the clinical context. Currently, only palliative treatments are performed. The α-phellandrene (α-phel) is a cyclic monoterpene found in essential oils of aromatic plants, which presents several biological activities, such as antinociceptive, antihyperalgesic and immunostimulant.

**Objectives:** This study aimed to investigate the action of α-phellandrene in chronic pain through in silico and in vivo approaches, aiming to develop a new therapeutic option for painful conditions, reducing analgesic doses and side effects.

**Methods:** The pharmacokinetic analysis of α-phel was performed by PreADMET online server. The software ACD/ChemSketch 14.0 was used to optimize the 3D structure of α-phel. Molecular docking was performed with the software AutoDock Tools 1.5.6 to evaluate the pharmacodynamics interactions of α-phel and opioid receptors.

---

**THU0453**

**THIRD OCCIPITAL NERVE RADIO-FREQUENCY UNDER FLUOROSCOPIC GUIDANCE IN MANAGEMENT OF CERVICOGENIC HEADACHE IN RHEUMATOID ARTHRITIS**

A. Alawamy1, M. Hassaniyen1, E. Talaat1, E. Kamel1. 1Assuit University, Assuit, Egypt

**Background:** Rheumatoid arthritis is a common type of autoimmune arthritis characterized by chronic inflammation. Cervical spine is often affected specially in long lasting disease.

**Objectives:** Evaluate efficacy of Third occipital nerve Radiofrequency under fluoroscopic guidance to treat refractory cervicogenic headache in RA patients.

**Methods:** The current study was revised and approved from the local ethical committee of Faculty of Medicine; Assuit University, then registered in the clinical trials under the number of NCT03823355. Inclusion criteria included, Patients who fulfilled the American College of Rheumatology (ACR) (2010) criteria for RA and suffering
from upper neck pain and/or headache due to bilateral 3rd occipital nerve involvement, excluding other local cervical spine pathologies was confirmed by MRI and previously failed conservative treatment for at least three months prior to enrollment. Sixty adult patients were randomly assigned to one of the two studied groups Group 1 (RF, n = 30), received bilateral Third occipital nerve radiofrequency under fluoroscopic guidance or Group 2 (control group, n = 30), received oral prednisolone 10 mg/day. The two groups were then followed-up with neck disability index (NDI), nocturnal neck pain VAS score and headache score every two weeks for three months. Sleep disturbance, sleep disability index were reassessed six months post intervention. Post interventional assessment was done by pain physician who were kept blind to the grouping process.

Results: Neck disability index (1 yr outcome), Nocturnal pain VAS, and severity of headache showed significant differences during the whole post-interventional study period. The patients in RF group demonstrated significant improvement of pain in comparison to baseline value over the whole six months with p-value < 0.001 as regard to the fore-mentioned three parameters. On the other aspect, the control group patients showed significant improvement in comparison to its baseline value after the 2nd, 12th and 24th weeks only as follows: 0.001, 0.003, 0.003 for the NDI (p values of 0.02,0.01, 0.01 for the nocturnal pain VAS), 0.001, 0.009, 0.005 for the headache VAS severity.

Conclusion: Radiofrequency of 3rd occipital nerve is effective in treatment of refractory cervicogenic headache in RA.

Disclosure of Interests: None declared

References:

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.241

THU0454  SOMATIC SYMPTOMS IN FIBROMYALGIA AND THEIR CORRELATION WITH DRUG TREATMENT

M. Antivallai, M. Agosti, A. Batticicotto, S. Costi, V. Giorgi, P. Sarzi Puttini.
1L. Sacco University Hospital, Rheumatology, Milano, Italy; L. Sacco University Hospital, Rheumatology, Milano, Italy; Ospedale di Circolo e Fondazione Macchi, Rheumatology, Varese, Italy

Background: Drug treatment in fibromyalgia (FM) is often disappointingly ineffective, and there are currently very few data to support therapeutic choices towards a personalized medicine approach.

Objectives: To evaluate the prevalence and severity of somatic symptoms in FM, and to study their relationship with drug treatments.

Methods: The study population consisted of 526 patients (471 F 55M, mean age 47.3±11.33 yrs) affected by FM not associated with other rheumatic diseases. All patients were required to compile a questionnaire reporting the presence of 42 somatic symptoms -as suggested (1) – in the last 7 days. Drug usage was assessed by interview.

Results: On average, patients reported the presence of 17.04±6.8 symptoms (range 4-35), with ample variations in the prevalence of different symptoms (Fig. 1), ranging from over 95% (fatigue and muscle pain) to less than 10%, sleep disturbance was reported by only 2 patients (0.4%). 31.1% of patients were not taking any drug for their FM. The most frequently used drugs were analgesics (ANA, 41.7%) followed by benzodiazepines (BD, 29.1%), SSRIs (16%), gabapentinoids (GABA, 14.4%), and NSRI (14.3%) (Fig. 2). Different drugs were associated with a different spectrum of somatic symptoms: as compared to non users, BD users reported a significantly higher (p< 0.05 by chi-square test) prevalence of irritable bowel (65.4% vs 52.3%), fatigue (98.7% vs 94.9%), thinking difficulties (78.4% vs 68.5%), muscle weakness (94.1% vs 81.7%), abdominal pain (55.6% vs 43.9%), insomnia (73.9% vs 56.6%), depression (63.4 % vs 37.2%), constipation (60.1% vs 42.9%), pain in upper abdomen (50.3% vs 40.2%), nausea (53.6% vs 38.3%), nervousness (71.9% vs 61.5%), chest pain (49.8 vs 37.7%), blurred vision (65.4% vs 53.6%), dry mouth (72.5% vs 52.3%), itching (56.2% vs 44.5%), vomiting (13.7% vs 7.8%), taste change (22.2% vs 12.7%), dry eyes (55.6% vs 41.0%), breath shortness (56.9% vs 47.7%), appetite loss (33.3% vs 19.7%), painful urination (15.0% vs 8.4%), and bladder spasms (18.3% vs 8.6%). NSRI users reported a significantly higher prevalence of thinking difficulties, constipation, blurred vision, dry mouth, wheezing, dry eyes, easy bruising. Among GABA users, there was a higher prevalence of thinking difficulties, numbness, insomnia, constipation, nausea, dry mouth, dry eyes, appetite loss, sun sensitivity, easy bruising, and bladder spasms. In no cases a higher prevalence of symptoms was recorded in drug non users vs users.

Conclusion: The usage of different drugs in FM is associated with different somatic symptoms. The higher prevalence of symptoms in drug users as compared to non users raises serious questions concerning the opportunity or the appropriateness of drug selection in FM.

THU0455  DIFFERENCES IN PSYCHIATRIC COMORBIDITIES AND LIFE ADVERSITIES BETWEEN PATIENTS WITH RHEUMATOID ARTHRITIS ASSOCIATED WITH FIBROMYALGIA AND PATIENTS WITH PRIMARY FIBROMYALGIA

F. Atzeni, M. Cirillo, I. F. Masala, E. Gerratana, D. Sangarì, G. Miceli, P. Sarzi-Puttini, A. Aciati, R. Rheumatology Unit, University of Messina, Messina, Italy; 2Trauma and Orthopedic Unit, Santissima Trinità Hospital, Cagliari, Italy; 3Department of Rheumatology, University Hospital ASST Fatebenefratelli Sacco, Milan, Italy; 4Department of Clinical Neurosciences, Hermanas Hospitalarias, Villa S. Benedetto Menni Hospital, Albese (Como), Italy; 5Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy, Como, Italy

Background: Patients with rheumatic arthritis (RA) continue to report significant pain despite apparent disease control by immunosuppressive drugs (1), leading to the hypothesis that central sensitisation (CS) plays a role in the chronic musculo-skeletal pain defining fibromyalgia (FM).

Objectives: The aim of our study was to evaluate the differences in psychiatric comorbidities and life adversities between patients with RA+FM and patients with primary FM (PFM).

Methods: In an observational cross-sectional study patients with PFM and AR+FM were consecutively recruited. The inclusion criteria were an age of 18-70 years; a diagnosis of RA according to the 2010 ACR classification criteria and FM according to the 1990 ACR criteria and 2016 ACR criteria. Lifetime diagnoses of major depression disorder (MDD), panic disorder (PD) and post-traumatic stress disorder (PTSD), three of the most frequently described psychiatric disorders among FM patients, were made with the Structured Clinical Interview for DSM-5. Depressive symptoms were measured using the Zung Self-rating Depression Scale (ZSDS). Childhood trauma was measured using the short form of the Childhood Trauma Questionnaire (CTQ) and stressful events were assessed.